Capital Investment Advisory Services’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Capital Investment Advisory Services’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-898	Closed	-$7K	–	1315
2019 Q3	$7K	Hold	898	–	–	﹤0.01%	1074
2019 Q2	$11K	Hold	898	–	–	﹤0.01%	956
2019 Q1	$5K	Buy	898 +500	+126%	+$2.43K	﹤0.01%	993
2018 Q4	$1K	Buy	+398	New	+$2.18K	﹤0.01%	1171

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Capital Investment Advisory Services's ZYNE Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 898 shares — an estimated $7K sold.

Capital Investment Advisory Services first reported a position in ZYNE in Q4 2018 and held it in 4 quarters. The position peaked at $11K in Q2 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

Capital Investment Advisory Services reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
Capital Investment Advisory Services sold 898 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $7K.
Capital Investment Advisory Services first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 4 quarters.
Capital Investment Advisory Services's Zynerba Pharmaceuticals, Inc position peaked at $11K in Q2 2019.
79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.